Science's next-generation single-molecule protein sequencing technology marks a new era in life sciences and biomedical research

Quantum-Si is a life sciences company
commercializing the first next-generation single-molecule protein sequencing platform.
Today, the company published a new study in the academic journal Science, showing how life science and biomedical research
can be transformed by single-molecule protein sequencing technology based on semiconductor chips and time-domain sequencing ™.
This first-of-its-kind sequencing process provides an unparalleled understanding of proteins that will drive drug discovery and diagnostics and bring revolutionary health and disease insights
to the world.
This unprecedented sequencing process provides an unparalleled understanding of proteins that will advance drug discovery and diagnosis and bring revolutionary health and disease insights
to the world.

Founded by world-renowned scientist, entrepreneur, and National Medal of Technology and Innovation winner Dr.
Jonathan Rothberg, Quantum-Si has developed the next generation of single-molecule protein sequencing technology to create better, more comprehensive ways to study proteins and influence the diagnosis of
modern diseases.

"I am proud and excited to share our first next-generation single-molecule protein sequencing technology with the world," said
Dr.
Rothberg, senior author of the paper.
"Just as the work I did with my first genomics collaborator on DNA sequencing earned Svante Pääbo a Nobel Prize, I fully expect the same profound and impactful discoveries
from the early adopters of Quantum-Si technology.
"

As described in Science magazine Real-time dynamic single-molecule protein sequencing on an integrated semiconductor device, Quantum-Si's semiconductor chips contain millions of wells that can catalog many proteins in parallel.
and understand how these proteins are modified at the single-molecule level
.
The company's next-generation sequencing systems utilize proteins and enzymes to detect and cleave amino acids derived from naturally occurring pathways
that take place in cells for similar processes.
This approach removes the barriers of complex chemistry and large, expensive equipment faced by other technologies, while providing the sensitivity, scalability, and accessibility needed to accelerate biomedical research
.

Study co-author Dr.
Brian D.
Reed, director of research at Quantum-Si, said: "The concept of massively parallel sequencing of individual protein molecules using small benchtop instruments was previously unthinkable
.
Researchers are already using indirect methods to understand proteins and have been waiting for tools that will revolutionize proteomics, just as DNA sequencing has done to genomics
.
Our platform's ability to map protein modifications, which are difficult to detect with other techniques, will greatly advance our understanding of
protein function and regulation in health and disease.
" ”

Additional information about the Quantum-Si single-molecule protein sequencing process:

• Mixing with dye-labeled N-terminal amino acid recognizers for real-time detection of single peptides while cleaving with aminopeptidase dynamic methods;

• annotate amino acids and identify peptide sequences by measuring fluorescence intensity, lifetime, and binding kinetics on integrated semiconductor chips;

• The recognizer recognizes multiple amino acids in an informative manner, making it possible to identify individual amino acid substitutions and post-translational modifications (PTMs), providing a more detailed picture
  of individual proteins and their changes for future disease recognition and prevention.